retatrutide ly3437943 glp-1 gip glucagon Triple Agonism Based Therapies for Obesity Retatrutide (LY3437943) | MyBioSource

Some symptoms may seem minor but can signal the need for dose adjustments or checks on other health issues

Peptide therapy is considered a safe treatment regimen

Many peptide protocols are cycled

Tang ASP, Hsu JTY, Chong SKS et al (2025) Glucagon-like peptide-1 receptor agonist in myocardial infarction and atherosclerotic cardiovascular disease risk reduction: a comprehensive meta-analysis of number needed to treat, efficacy and safety

Therefore, weight-loss interventions should be considered an adjunct strategy for regulating prolactin rather than a direct means of treating hyperprolactinemia

The healthcare provider must explain why continuing the treatment is vital and how it contributes to the patients health status